Jan Endrikat

ORCID: 0000-0001-6063-5014 · 6 papers in corpus · active 2007-2017

Study types

  • article 4
  • letter 1
  • review 1

Condition tags

  • endometriosis 1
  • chronic_pelvic_pain 1
letter 2017
Letter to the editor in response to “Minimal clinically important difference for pain on the VAS scale and the relation to quality of life in women with endometriosis” by Wickström and Edelstam
Sexual & reproductive healthcare : official journal of the Swedish Association of Midwives ·doi:10.1016/j.srhc.2017.10.004
review 2011
Ovulation inhibition doses of progestins: a systematic review of the available literature and of marketed preparations worldwide
·doi:10.1016/j.contraception.2011.04.009
article 2008
Original research article Ovulation inhibition with four variations of a four-phasic estradiol valerate/dienogest combined oral contraceptive: results of two prospective, randomized, open-label studies ☆,☆☆

Background: Attempts to improve the tolerability of combined oral contraceptives (COCs) have included the substitution of ethinylestradiol (EE) with 17β-estradiol (E2). However, this has proved unsatisfactory, specifically in terms of cycle…

article 2008
Ovulation inhibition with four variations of a four-phasic estradiol valerate/dienogest combined oral contraceptive: results of two prospective, randomized, open-label studies
·doi:10.1016/j.contraception.2008.05.004
article 2007
A multicenter, prospective, randomized, double-blind, placebo-controlled study to investigate the efficacy of a continuous-combined hormone therapy preparation containing 1 mg estradiol valerate/2 mg dienogest on hot flushes in postmenopausal women
Maturitas ·doi:10.1016/j.maturitas.2007.08.004
article 2007
A one-year randomized double-blind, multicentre study to evaluate the effects of an oestrogen-reduced, continuous combined hormone replacement therapy preparation containing 1 mg oestradiol valerate and 2 mg dienogest on metabolism in postmenopausal women
·doi:10.1080/13625180701441030

OBJECTIVES: To evaluate the impact of an oestrogen-reduced, continuous combined hormone replacement therapy preparation containing 1 mg oestradiol valerate (1EV) and 2 mg dienogest (2DNG) on metabolism. METHODS: In a randomized double-blind…